Herbalife Ltd. (NYSE: HLF), a leading health and wellness company, has announced an agreement to acquire certain assets from Bioniq, a UK-based personalized supplements company focused on making nutrition more accessible and data-driven. The move supports Herbalife’s strategy to evolve into a technology-enabled, data-driven health and wellness platform.
According to Herbalife CEO Stephan Gratziani, the future of wellness lies in personalization informed by data. He noted that integrating Bioniq’s personalized supplement technology with Herbalife’s Pro2col platform and its global distributor network will enhance the company’s ability to deliver customized wellness solutions at scale.
Founded in 2019, Bioniq specializes in creating personalized supplement formulations using its proprietary product personalization engine, along with individual health data and biomarker analysis. Its solutions are designed for a wide range of users, from everyday consumers to elite athletes, including Cristiano Ronaldo.
The acquisition builds on Herbalife’s earlier investments in Pro2col and Link BioSciences, further strengthening its ability to offer a broader range of personalized nutrition products across multiple delivery formats. By combining Bioniq’s technology with Herbalife’s global manufacturing capabilities, the company aims to accelerate the expansion of personalized nutrition worldwide.
Bioniq founder Vadim Fedotov shared that the company was built on the vision of helping individuals optimize their well-being through science-driven, data-informed nutrition. He expressed excitement about joining Herbalife to further scale this mission through its global network.
Cristiano Ronaldo, a long-time Herbalife partner and Bioniq user, also highlighted the importance of personalized nutrition in supporting performance and overall health. He noted that the collaboration will help more people access tailored nutrition solutions that can support their wellness and performance goals.
The transaction is expected to close in the second quarter of 2026, subject to regulatory approvals and closing conditions. The deal includes a $55 million purchase price, structured with an initial $10 million payment and additional payments over five years, along with up to $95 million in contingent payments based on performance.
As part of the agreement, Herbalife also secured a call option to acquire Bioniq LAB, a platform focused on small molecules and peptides, giving the company strategic flexibility to explore future opportunities in this space.
Bioniq’s personalized supplements are expected to become available later this year through Herbalife’s independent distributors in select markets in Europe and the United States, with further expansion planned in additional regions.
With this acquisition, Herbalife continues to strengthen its position in the growing personalized nutrition sector, aligning technology, data, and global distribution to deliver more tailored health and wellness solutions to consumers worldwide.
